Clinical TrialMay 14, 2026, 08:07 AM
Genprex Diabetes Gene Therapy Shows Positive Preclinical Data
AI Summary
Genprex, Inc. announced positive preclinical data for its diabetes gene therapy drug candidate, GPX-002 (Pdx1/MafA gene therapy), presented at the 2026 ASGCT Annual Meeting. The data demonstrated that the therapy successfully reversed hyperglycemia in Type 2 diabetic mouse models. Key findings included improved beta-cell function and maturation, with an increase in mature insulin granules, suggesting a fundamental approach to treating T2D. The company believes this preclinical data is a pivotal step towards a potentially transformative treatment offering long-term glycemic control.
Key Highlights
- Genprex presented positive preclinical data for its diabetes gene therapy, GPX-002.
- Data was showcased at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.
- The gene therapy reversed hyperglycemia in Type 2 diabetic (T2D) mouse models.
- Preclinical results showed improved beta-cell function and maturation with PM treatment.
- Electron microscopy revealed increased mature insulin granules in treated mice.
- Transcriptomic analysis indicated a shift in beta-cells to a more mature state.
- The company believes this is a pivotal step towards a transformative T2D treatment.
- Genprex aims to offer long-term glycemic control by addressing beta-cell dysfunction.
Price Impact
More from GNPX